Study on the role of vasoactive substances in the pathogenesis of hypertension in patients with sleep apnea syndrome
- VernacularTitle:血管活性物质在睡眠呼吸暂停综合征合并高血压中作用的研究
- Author:
Guanghui CHEN
;
Shiwen WAN
;
Wenli ZHANG
- Publication Type:Journal Article
- Keywords:
sleep apnea syndrome;
hypertension;
vasoactive substance
- From:
Medical Journal of Chinese People's Liberation Army
1983;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the difference of the morbidity rate of hypertension among patients with sleep apnea syndrome (SAS) in different stages, and the change in the blood levels of some vasoactive substances and their correlations with severity of SAS, in order to further explore the mechanism of hypertension caused by SAS. Methods 63 patients suspected to suffer from SAS were enrolled, and they were divided into normal, mild, moderate, and severe SAS groups according to respiratory disorder index (RDI) obtained by polysomnography (PSG) monitoring. The diagnosis of hypertension was made by the measurement of blood pressure and 24-hour dynamic measurement of blood pressure. Blood levels of angiotesnin Ⅱ (Ang Ⅱ), endothelin-1 (ET-1), throboxane B2 (TXB2), calcium gene related protein (CGRP), 6-keto-protagladin factor1?(6-keto-PGF1?) were determined with radioimmunoassay. Results The mobidity rate of hypertension was significantly higher in moderate and severe SAS group than that in the normal group (P0.05). Correlative analysis showed that the blood levels of Ang Ⅱ, ET-1, TXB2 were positively correlative to RDI (r=0.594, 0.523, 0.574, respectively, P0.05). Conclusion SAS is significantly related to the incidence of hypertension. Vasoactive substances with vasoconstrictive effect such as Ang Ⅱ, ET-1, TXB2 play an important role in the pathogenesis and development of hypertension in SAS patients than those with vasodilative effect such as CGRP and 6-keto-PGF1?.
